Arcus Biosciences, Inc. Profile Avatar - Palmy Investing

Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 cl…

Biotechnology
US, Hayward [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Arcus Biosciences, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Arcus Biosciences, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Arcus Biosciences, Inc..

End of RCUS's Analysis
CIK: 1724521 CUSIP: 03969F109 ISIN: US03969F1093 LEI: - UEI: -
Secondary Listings
RCUS has no secondary listings inside our databases.